An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema.


Journal

RNA (New York, N.Y.)
ISSN: 1469-9001
Titre abrégé: RNA
Pays: United States
ID NLM: 9509184

Informations de publication

Date de publication:
02 2019
Historique:
received: 20 09 2018
accepted: 20 11 2018
pubmed: 23 11 2018
medline: 21 3 2019
entrez: 23 11 2018
Statut: ppublish

Résumé

Hereditary angioedema (HAE) is a genetic disorder mostly caused by mutations in the C1 esterase inhibitor gene (C1INH) that results in poor control of contact pathway activation and excess bradykinin generation. Bradykinin increases vascular permeability and is ultimately responsible for the episodes of swelling characteristic of HAE. We hypothesized that the use of RNA interference (RNAi) to reduce plasma Factor XII (FXII), which initiates the contact pathway signaling cascade, would reduce contact pathway activation and prevent excessive bradykinin generation. A subcutaneously administered GalNAc-conjugated small-interfering RNA (siRNA) targeting

Identifiants

pubmed: 30463937
pii: rna.068916.118
doi: 10.1261/rna.068916.118
pmc: PMC6348991
doi:

Substances chimiques

Complement C1 Inhibitor Protein 0
Kininogens 0
RNA, Small Interfering 0
SERPING1 protein, human 0
Factor XII 9001-30-3
Bradykinin S8TIM42R2W

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

255-263

Informations de copyright

© 2019 Liu et al.; Published by Cold Spring Harbor Laboratory Press for the RNA Society.

Références

J Thromb Haemost. 2005 Dec;3(12):2815-7
pubmed: 16359524
Blood. 1988 May;71(5):1334-40
pubmed: 2451949
Ann Allergy Asthma Immunol. 2014 May;112(5):413-8
pubmed: 24484972
Mol Ther. 2018 Mar 7;26(3):708-717
pubmed: 29456020
Blood. 1998 Mar 15;91(6):2010-4
pubmed: 9490684
Cell. 2009 Dec 11;139(6):1143-56
pubmed: 20005807
J Allergy Clin Immunol. 2016 Nov;138(5):1414-1423.e9
pubmed: 27130860
Am J Rhinol Allergy. 2011 Nov-Dec;25(6):373-8
pubmed: 22185738
Drug Metab Rev. 1984;15(4):841-69
pubmed: 6437780
N Engl J Med. 2017 May 4;376(18):e38
pubmed: 28467871
Mol Immunol. 2001 Aug;38(2-3):161-73
pubmed: 11532278
Curr Opin Hematol. 2000 Sep;7(5):261-5
pubmed: 10961574
N Engl J Med. 2002 Aug 22;347(8):621-2
pubmed: 12192030
Immunol Allergy Clin North Am. 2013 Nov;33(4):457-70
pubmed: 24176211
J Clin Invest. 2002 Apr;109(8):1057-63
pubmed: 11956243
World Allergy Organ J. 2010 Sep;3(9 Suppl):S39-40
pubmed: 23282869
J Allergy Clin Immunol. 2009 Jul;124(1):129-34
pubmed: 19477491
Nucleic Acid Ther. 2013 Jun;23(3):175-87
pubmed: 23582057
J Thromb Haemost. 2016 May;14(5):995-1007
pubmed: 26613657
N Engl J Med. 2017 Aug 31;377(9):819-828
pubmed: 28691885
Am J Hum Genet. 2006 Dec;79(6):1098-104
pubmed: 17186468
Thromb Haemost. 2014 Nov;112(5):868-75
pubmed: 25187064
N Engl J Med. 2017 Jan 5;376(1):41-51
pubmed: 27959715
PLoS One. 2016 Sep 29;11(9):e0163958
pubmed: 27685806
J Intern Med. 2015 Dec;278(6):571-85
pubmed: 26373901
J Clin Invest. 2018 Mar 1;128(3):944-959
pubmed: 29376892
J Am Chem Soc. 2014 Dec 10;136(49):16958-61
pubmed: 25434769
Eur Ann Allergy Clin Immunol. 2013 Feb;45(1):7-16
pubmed: 23678554
J Clin Invest. 2015 Aug 3;125(8):3132-46
pubmed: 26193639
J Allergy Clin Immunol. 2013 Jun;131(6):1708-11
pubmed: 23265861
Allergy. 2015 Dec;70(12):1661-4
pubmed: 26248961
N Engl J Med. 2017 Feb 23;376(8):717-728
pubmed: 28225674
Mol Ther. 2017 Jan 4;25(1):71-78
pubmed: 28129130
J Pharmacol Exp Ther. 2000 Jul;294(1):263-9
pubmed: 10871321
Hellenic J Cardiol. 2012 Mar;53(2):91-4
pubmed: 22484773
FASEB J. 2000 Dec;14(15):2589-600
pubmed: 11099478
Immunobiology. 2002 Sep;205(4-5):542-51
pubmed: 12396014
ACS Chem Biol. 2015 May 15;10(5):1181-7
pubmed: 25730476
Blood. 2014 Mar 13;123(11):1739-46
pubmed: 24408325

Auteurs

Jingxuan Liu (J)

Alnylam Pharmaceuticals, Cambridge, Massachusetts 02142, USA.

June Qin (J)

Alnylam Pharmaceuticals, Cambridge, Massachusetts 02142, USA.

Anna Borodovsky (A)

Alnylam Pharmaceuticals, Cambridge, Massachusetts 02142, USA.

Timothy Racie (T)

Alnylam Pharmaceuticals, Cambridge, Massachusetts 02142, USA.

Adam Castoreno (A)

Alnylam Pharmaceuticals, Cambridge, Massachusetts 02142, USA.

Mark Schlegel (M)

Alnylam Pharmaceuticals, Cambridge, Massachusetts 02142, USA.

Martin A Maier (MA)

Alnylam Pharmaceuticals, Cambridge, Massachusetts 02142, USA.

Tracy Zimmerman (T)

Alnylam Pharmaceuticals, Cambridge, Massachusetts 02142, USA.

Kevin Fitzgerald (K)

Alnylam Pharmaceuticals, Cambridge, Massachusetts 02142, USA.

James Butler (J)

Alnylam Pharmaceuticals, Cambridge, Massachusetts 02142, USA.

Akin Akinc (A)

Alnylam Pharmaceuticals, Cambridge, Massachusetts 02142, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH